Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Teva Pharmaceutical Sp Adr / Equity Bottom-Up

<ul><li>Teva Pharmaceuticals has taken another step in its broader shift toward innovative medicines by bidding for certain neuroscience assets of BioXcel Therapeutics through a court-supervised Chapter 11 sale process.</li><li>Importantly, Teva is not proposing to acquire BioXcel Therapeutics in its entirety; it is acting as the stalking-horse bidder for assets that include IGALMI and BXCL501, BioXcel’s dexmedetomidine sublingual film.</li><li>Teva would pay $57.5 million upfront and potentially another $67.5 million through regulatory, timing, and sales-related contingent payments if it ultimately wins the auction.</li></ul>

Teva Pharmaceuticals has taken another step in its broader shift toward innovative medicines by bidding for certain neuroscience assets of BioXcel Therapeutics through a court-supervised Chapter 11 sale process.Importantly, Teva is not proposing to acquire BioXcel Therapeutics in its entirety; it is acting as the stalking-horse bidder for assets that include IGALMI and BXCL501, BioXcel’s dexmedetomidine sublingual film.Teva would pay $57.5 million upfront and potentially another $67.5 million through regulatory, timing, and sales-related contingent payments if it ultimately wins the auction.

Teva Pharmaceuticals Takeover Strategy Targets A High-Potential Neuroscience Asset!

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Teva Pharmaceutical Industries / Equity Bottom-Up

<ul>
 <li>Teva is executing a "Pivot to Growth"strategy, shifting focus from a scale-driven generics business to higher-margin innovative drugs, complex generics, and biosimilars to drive future profitability.</li>
 <li>Significant headwinds remain from substantial debt leverage and large-scale opioid litigation settlements, which will continue to impact cash flow and financial flexibility over the coming years.</li>
 <li>Growth in key innovative products, particularly AUSTEDO®, AJOVY®, and UZEDY®, is critical to the success of the turnaround strategy and is beginning to show positive results, contributing to recent revenue growth and improved credit ratings.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  Teva is executing a "Pivot to Growth"strategy, shifting focus from a scale-driven generics business to higher-margin innovative drugs, complex generics, and biosimilars to drive future profitability.
  Significant headwinds remain from substantial debt leverage and large-scale opioid litigation settlements, which will continue to impact cash flow and financial flexibility over the coming years.
  Growth in key innovative products, particularly AUSTEDO®, AJOVY®, and UZEDY®, is critical to the success of the turnaround strategy and is beginning to show positive results, contributing to recent revenue growth and improved credit ratings.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Teva Pharmaceutical Industries (TEVA IT) - Aug 2026

<ul>
 <li>Teva is successfully executing a "Pivot to Growth"strategy, shifting focus from its legacy, low-margin generics business to a higher-margin, innovative portfolio of specialty drugs.</li>
 <li>Growth is being driven by key innovative brands AUSTEDO, AJOVY, and UZEDY, which collectively grew 43% in local currency to over $1 billion in a recent quarter, offsetting declines in the generics segment.</li>
 <li>While the company is showing operational improvements and reducing debt, it still faces significant risks from intense competition and pricing pressure in the generics market, potential regulatory headwinds, and reliance on the successful execution of its pipeline.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  Teva is successfully executing a "Pivot to Growth"strategy, shifting focus from its legacy, low-margin generics business to a higher-margin, innovative portfolio of specialty drugs.
  Growth is being driven by key innovative brands AUSTEDO, AJOVY, and UZEDY, which collectively grew 43% in local currency to over $1 billion in a recent quarter, offsetting declines in the generics segment.
  While the company is showing operational improvements and reducing debt, it still faces significant risks from intense competition and pricing pressure in the generics market, potential regulatory headwinds, and reliance on the successful execution of its pipeline.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Teva Pharmaceutical Sp Adr (TEVA US) - Aug 2026

<ul><li>President Donald Trump’s proposed 100% tariff on imported generic drugs delivered an immediate shock to Teva Pharmaceutical Industries, sending its shares down nearly 4% as investors considered the consequences for one of the world’s largest generic-medicine manufacturers.</li><li>The concern is understandable: generic drugs operate on thin margins, and sharply higher import costs could be difficult to absorb without increasing prices or relocating production.</li><li>Yet Wall Street’s response has been notably less pessimistic.</li></ul>

President Donald Trump’s proposed 100% tariff on imported generic drugs delivered an immediate shock to Teva Pharmaceutical Industries, sending its shares down nearly 4% as investors considered the consequences for one of the world’s largest generic-medicine manufacturers.The concern is understandable: generic drugs operate on thin margins, and sharply higher import costs could be difficult to absorb without increasing prices or relocating production.Yet Wall Street’s response has been notably less pessimistic.

Teva Just Got Hit By Trump—So Why Does Wall Street See 38% Upside?

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>Large-Cap indexes (S&amp;P 500, Nasdaq 100, and DJI) remain bullish, all hitting new all-time highs last week while continuing to find short-term support at their respective 20-day MAs.</li>
<li>Mid-Caps (S&amp;P 400, Russell Mid-Cap) starting another leg higher following breakouts from 2-month consolidations. Small-caps (S&amp;P 600, Russell 2000) are likely to follow in the footsteps of large- and mid-caps.</li>
<li>Small-Cap indexes have been consolidating for 2.5 months following the historic rally from late-October to late-December 2023, a healthy sign. We expect they are gearing-up for another similar move higher.</li>
</ul>


Large-Cap indexes (S&amp;P 500, Nasdaq 100, and DJI) remain bullish, all hitting new all-time highs last week while continuing to find short-term support at their respective 20-day MAs.
Mid-Caps (S&amp;P 400, Russell Mid-Cap) starting another leg higher following breakouts from 2-month consolidations. Small-caps (S&amp;P 600, Russell 2000) are likely to follow in the footsteps of large- and mid-caps.
Small-Cap indexes have been consolidating for 2.5 months following the historic rally from late-October to late-December 2023, a healthy sign. We expect they are gearing-up for another similar move higher.


U.S. Dollar Rolling Over; Small-Caps to Follow Mid- And Large-Caps to New Highs; Buys in Cons. Disc.

Israel

Teva Pharmaceutical Industries Limited operates as a pharmaceutical company. The Company develops, manufactures, and markets generic and branded human pharmaceuticals, as well as active pharmaceutical ingredients. Teva Pharmaceutical Industries serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Teva Pharmaceutical Industries (TEVA IT)

Teva Pharmaceuticals Takeover Strategy Targets A High-Potential Neuroscience Asset!

Teva Pharmaceuticals has taken another step in its broader shift toward innovative medicines by bidding for certain neuroscience assets of BioXcel...

Baptista Research

Primer: Teva Pharmaceutical Industries (TEVA IT) - Aug 2026

Teva is executing a "Pivot to Growth"strategy, shifting focus from a scale-driven generics business to higher-margin innovative drugs, complex...

αSK Primers

Primer: Teva Pharmaceutical Sp Adr (TEVA US) - Aug 2026

Teva is successfully executing a "Pivot to Growth"strategy, shifting focus from its legacy, low-margin generics business to a higher-margin,...

αSK Primers

Teva Just Got Hit By Trump—So Why Does Wall Street See 38% Upside?

President Donald Trump’s proposed 100% tariff on imported generic drugs delivered an immediate shock to Teva Pharmaceutical Industries, sending...

Baptista Research

U.S. Dollar Rolling Over; Small-Caps to Follow Mid- And Large-Caps to New Highs; Buys in Cons. Disc.

U.S. Dollar $DXY Rolling Over; 10- and 30-Yr Treasury Yields Hit Major Resistance; Small-Caps to Follow Mid- and Large-Caps to New Highs $IWM $RTY...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)